Tadaoka N, Takayama S, Sekine C, Fujimori T, Nimura H, Tsutsumi J, Kashimura H, Sano Y, Hirai K, Aoki T
Dept. of Surgery II, Jikei University School of Medicine.
Gan To Kagaku Ryoho. 1993 Apr;20(6):799-803.
Neoadjuvant chemotherapy with CDDP and UFT was performed on far advanced gastric carcinoma cases whose curative resection was impossible. These trials were carried out on 10 patients who had Borrmann 4 type carcinoma. PR was found in 6 cases, for an efficacy rate of 60% (6/10). The DNA content in gastric carcinoma was determined before and after treatment by flow cytometry. The relationship between the change of DNA ploidy pattern and effects of chemotherapy was investigated. Aneuploidy was found in 6 of 10 patients (60.0%). DNA ploidy patterns showed no correlation with effectiveness. In aneuploid cases, the group of responders showed seemingly the change of ploidy pattern, from aneuploid to diploid. In non-responders the percentage of aneuploid cells increased. In diploid cases, an accumulation of S-phase fraction was observed in the group of responders. These results suggested that DNA ploidy analysis may provide additional diagnostic criteria for better assessment of chemotherapeutic effects.
对无法进行根治性切除的进展期胃癌病例采用顺铂（CDDP）和替加氟（UFT）进行新辅助化疗。对10例Borrmann 4型癌患者进行了这些试验。6例患者出现部分缓解（PR），有效率为60%（6/10）。治疗前后通过流式细胞术测定胃癌中的DNA含量。研究了DNA倍体模式变化与化疗效果之间的关系。10例患者中有6例（60.0%）为非整倍体。DNA倍体模式与疗效无相关性。在非整倍体病例中，有反应者组似乎出现了倍体模式的变化，从非整倍体变为二倍体。在无反应者中，非整倍体细胞的百分比增加。在二倍体病例中，有反应者组观察到S期分数的积累。这些结果表明，DNA倍体分析可能为更好地评估化疗效果提供额外的诊断标准。
